Yasser M. El-Gamal

Role: Verve Therapeutics
Location: Cambridge, MA, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Yasser M. El-Gamal

As Vice President of Legal Affairs & Chief IP Counsel and a member of Verve\'s management…

Experience

Verve Therapeutics
Present

Skills

Mergers & Acquisitions
Monetization
Mergers
Legal Opinions
Technology Transfer
Trials
Copyright Law
Corporate Law
Semiconductors
Patentability
Ip Portfolio Development and Counseling
Patent Prosecution
Mediation
Biotechnology
Arbitration
Patent Litigation
Unfair Competition
Client Counseling
Prosecution
Litigation
Due Diligence
Civil Litigation
Ip Monetization
Joint Ventures
Trademarks
Trademark Infringement
Intellectual Property
Trade Secrets
Patents
Legal Writing
Licensing
Mergers
Start-Ups
Legal Research
Commercial Litigation

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@vervetx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Verve Therapeutics

Biotechnology Research · 160 employees · Founded 2018 · Boston, Massachusetts, United States

Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company\'s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis.

vervetx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.